Global Sinusitis Drugs Market 2019-2023
A key factor driving the growth of the global sinusitis drugs market is
the rise in the prevalence of sinusitis. Sinus infection is caused due
to the fluid entrapment in the sinus glands, eventually inducing the
propagation of germs in these glands. Allergies, pollutants, and fungal
infections are vital factors responsible for the rising incidence of
sinusitis. This has led to the need to develop and manufacture sinusitis
drugs among the several stakeholders of the healthcare industry. Growing
awareness about the symptoms of the disease is propelling an early
diagnosis resulting in better clinical outcomes. This will foster the
growth of the sinusitis drugs market during the forecast period.
Global sinusitis drugs market: Advent of biologics
The emergence of biologics is one of the critical trends gaining traction in the sinusitis drugs market. Among the biologics that are currently being evaluated, omalizumab has evolved as the most suitable candidate. Omalizumab, a recombinant humanized monoclonal antibody, has been approved for the treatment of severe allergic asthma in the US and Europe. Scientists are evaluating Omalizumab on the parameters of safety and efficacy for the treatment of chronic rhinosinusitis with nasal polyps. Successful launch of biologics such as omalizumab is likely to drive the sinusitis drugs market growth in the forthcoming years.
Global sinusitis drugs market: Segmentation
analysis
This market research report segments the global sinusitis drugs market by product (steroid nasal sprays, antibiotics, decongestants, and other drugs) and geographic regions (North America, Europe, Asia, and ROW).
North America led the market in 2018, followed by Europe, Asia, and ROW, respectively. The market growth in North America can be attributed to the increased investments in R&D by large pharmaceutical companies and the presence of a proper regulatory framework for the approval of new drugs in the region.
Global sinusitis drugs market: Advent of biologics
The emergence of biologics is one of the critical trends gaining traction in the sinusitis drugs market. Among the biologics that are currently being evaluated, omalizumab has evolved as the most suitable candidate. Omalizumab, a recombinant humanized monoclonal antibody, has been approved for the treatment of severe allergic asthma in the US and Europe. Scientists are evaluating Omalizumab on the parameters of safety and efficacy for the treatment of chronic rhinosinusitis with nasal polyps. Successful launch of biologics such as omalizumab is likely to drive the sinusitis drugs market growth in the forthcoming years.
This market research report segments the global sinusitis drugs market by product (steroid nasal sprays, antibiotics, decongestants, and other drugs) and geographic regions (North America, Europe, Asia, and ROW).
North America led the market in 2018, followed by Europe, Asia, and ROW, respectively. The market growth in North America can be attributed to the increased investments in R&D by large pharmaceutical companies and the presence of a proper regulatory framework for the approval of new drugs in the region.
Comments
Post a Comment